Methods
We report the use of Omalizumab in three patients presenting CSU attended at Clinical Immunology outpatient service of a Brazilian Reference Center.
Results
Three women (50, 74 and 28 years old) with a history of urticaria for 10, 7 and 6 years, respectively. Two of them reported intermitent angioedema. Urticaria activity score (UAS) ranged from 4 to 6 in all of them. Laboratory investigation, including autoimmunity and immunodeficiency screening, was normal. Total IgE levels were high in two of them. All three had positive autologous serum skin test (ASST). All of them had used high doses of antihistamines, oral corticosteroids, hydroxychloroquine, dapsone, doxepin, amitriptyline, with no improvement. One of them also used cyclosporine A and intravenous immunoglobulin G for 3 times with a 3 week interval. Infusion was discontinued because patient presented diarrhea, abdominal pain and urticaria exacerbation.
Therefore, we decided to use Omalizumab. After treatment consent form signature, they started on 300 mg Omalizumab subcutaneous every 4 weeks.
Patient 1 (50 y) -Showed improvement on the first 48 hours after Omalizumab infusion and has kept UAS = zero until now (for 18 months), without any other therapy Patient 2 (74 y) -Showed UAS improvement from 6 to 2 after six months using Omalizumab. However, she still needs to use low doses of antihistamines and doxepin.
Patient 3 (28 y) -Showed improvement in the first week treatment, and has kept UAS = zero. She has kept using Omalizumab for 5 months now, but she still needs low doses of antihistamines.
Conclusions
Our experience has shown Omalizumab to be an effective treatment option for patients with refractory CSU, as directed by the EAACI/GA2LEN/EDF & WAO guidelines.
